Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04312282
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT03952325
- Locations
- 🇺🇸
Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists and Research Institute, West Palm Beach, Florida, United States
🇺🇸Florida Cancer Specialists and Research Institute - Panhandle Region, Tallahassee, Florida, United States
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03858972
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Rocky Mountain Cancer Center, Lakewood, Colorado, United States
🇺🇸Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 685
- Registration Number
- NCT03326674
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Arizona Oncology Associates, P.C. - HOPE, Tucson, Arizona, United States